Vol 6 (2021): Continuous Publishing
Review paper
Published online: 2021-03-22

open access

Page views 6952
Article views/downloads 3062
Get Citation

Connect on Social Media

Connect on Social Media

Effects of preservatives used in ocular medications on the eye: a comparative review

Rupankar Sarkar1
Ophthalmol J 2021;6:44-52.


Preservatives are added to eye drops in order to increase the shelf life of these medications. However, these preservatives
may have some adverse effects on the eye. Various adverse effects of preserved ocular medications have been pointed
out by multiple investigators time and again. These preservatives are added to most ocular medicines in today’s practice. Given the fact that many patients need to instill these medications for long periods, such as anti-glaucoma medications, the adverse effects of these preservatives need to be taken into account. Benzalkonium chloride is the most widely used preservative in ocular medications and has a lot of adverse effects. Various other alternative preservatives have been developed in more recent times. In this article, a broad overview regarding various researches exploring the different adverse effects of these preservatives has been compiled and presented comparatively.

Article available in PDF format

View PDF Download PDF file


  1. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17(4): 419–425.
  2. Freeman P, Kahook M. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Exp Rev Ophthalmol. 2014; 4(1): 59–64.
  3. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23(5): 490–496.
  4. Kahook M. Travoprost Z ophthalmic solution with sofZia: clinical safety and efficacy. Exp Rev Ophthal. 2014; 2(3): 363–368.
  5. Tomić M, Kaštelan S, Soldo KM, et al. Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma. Biomed Res Int. 2013; 2013: 603782.
  6. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998; 82(1): 39–42.
  7. Aihara M, Oshima H, Araie M, et al. EXTraKT study group. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study. Acta Ophthalmol. 2013; 91(1): e7–ee14.
  8. Crichton ACS, Vold S, Williams JM, et al. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013; 30(3): 260–270.
  9. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009; 19(4): 572–579.
  10. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88(3): 329–336.
  11. Ashraf H, Ahmad S, Sarkar R, et al. Topical Prostaglandin Analogues with and without Preservatives on Tear Film Stability in the Long-Term Treatment of Glaucoma. J Evid Based Med Healthc. 2020; 7(16): 823–826.
  12. Kim EJ, Kim YH, Kang SH, et al. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013; 27(6): 446–453.
  13. Baudouin C, Riancho L, Warnet JM, et al. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007; 48(9): 4123–4128.
  14. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010; 27(11): 837–845.
  15. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999; 40(3): 619–630.
  16. Sherwood MB, Grierson I, Millar L, et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96(3): 327–335.
  17. Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990; 108(11): 1543–1548.
  18. Williams DE, Nguyen KD, Shapourifar-Tehrani S, et al. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992; 33(7): 2233–2241.
  19. Takahashi N. [Cytotoxic effects of antiglaucoma agents on cultured human conjunctival cells (author's transl)]. Nippon Ganka Gakkai Zasshi. 1981; 85(8): 1046–1052.
  20. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994; 232(9): 561–565.
  21. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980; 19(3): 308–313.
  22. Kim JH, Kim EJ, Kim YH, et al. In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study. Korean J Ophthalmol. 2015; 29(4): 270–279.
  23. Meda R, Wang Q, Paoloni D, et al. The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. Br J Ophthalmol. 2017; 101(2): 120–125.
  24. Egorov EA, Astahov Y, Erichev VP, et al. Evaluation of efficacy and safety of preservative-free tafluprost 0, 0015% eye drops in POAG and ophthalmohypertension. RMJ Clin Ophthalmol. 2015; 15(1): 1–6.
  25. Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016; 10: 445–454.
  26. Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010; 248(12): 1757–1764.
  27. Sezgin Akçay Bİ, Güney E, Bozkurt TK, et al. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study. J Ocul Pharmacol Ther. 2014; 30(7): 548–553.
  28. Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014; 98(7): 926–931.
  29. Ranno S, Sacchi M, Brancato C, et al. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients. ScientificWorldJournal. 2012; 2012: 804730.
  30. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf ). 2008; 242: 14–19.
  31. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf ). 2008; 242: 7–13.
  32. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17(3): 341–349.
  33. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009; 19(4): 572–579.
  34. Kanamoto T, Kiuchi Y, Tanito M, et al. Ocular Surface Disease and Glaucoma Study Group. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015; 31(3): 156–164.
  35. Rouland JF, Traverso CE, Stalmans I, et al. T2345 Study Group. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013; 97(2): 196–200.
  36. Ohtani S, Shimizu K, Nejima R, et al. Conjunctival Bacteria Flora of Glaucoma Patients During Long-Term Administration of Prostaglandin Analog Drops. Invest Ophthalmol Vis Sci. 2017; 58(10): 3991–3996.
  37. Honda R, Toshida H, Suto C, et al. Effect of long-term treatment with eyedrops for glaucoma on conjunctival bacterial flora. Infect Drug Resist. 2011; 4: 191–196.
  38. Sen EM, Yilmaz MB, Dansuk Z, et al. Effect of chronic topical glaucoma medications on aerobic conjunctival bacterial flora. Cornea. 2009; 28(3): 266–270.
  39. Kestelyn PhA, Kestelyn PhG, De Bacquer D, et al. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. Int Ophthalmol. 2019; 39(1): 105–109.
  40. Stevens AM, Kestelyn PA, De Bacquer D, et al. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012; 90(3): e221–e224.
  41. Abe RY, Zacchia RS, Santana PR, et al. Effects of benzalkonium chloride on the blood-aqueous and blood-retinal barriers of pseudophakic eyes. J Ocul Pharmacol Ther. 2014; 30(5): 413–418.
  42. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res. 1989; 49(1): 1–12.
  43. Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003; 241(12): 1037–1043.
  44. Desbenoit N, Schmitz-Afonso I, Baudouin C, et al. Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Anal Bioanal Chem. 2013; 405(12): 4039–4049.
  45. Chandrasekaran S, Cumming RG, Rochtchina E, et al. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology. 2006; 113(3): 417–424.
  46. Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003; 121(6): 835–839.
  47. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001; 119(3): 387–394.
  48. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999; 117(1): 34–40.
  49. Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J Glaucoma. 2013; 22(9): 730–735.
  50. Öztürker ZK, Öztürker C, Bayraktar S, et al. Does the use of preoperative antiglaucoma medications influence trabeculectomy success? J Ocul Pharmacol Ther. 2014; 30(7): 554–558.
  51. Broadway DC, Grierson I, Stürmer J, et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114(3): 262–267.
  52. Baudouin C. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res. 1996; 16(1): 29–41.